Navigation Links
Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
Date:9/2/2013

ticipates that it will be required to conduct at least one confirmatory Phase III clinical trial of tirasemtiv in ALS patients which will require significant additional funding, and it may be unable to obtain such additional funding on acceptable terms, if at all; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Amgen's and Astellas' decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil and CK-2127107, respectively; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; Cytokinetics may be unable to enter into future collaboration agreements for its drug candidates and programs on acceptable terms, if at all; standards of care may change, rendering Cytokinetics' drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, includ
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amgen To Participate At Citis 8th Annual Biotech Conference
2. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
3. Amgen to Highlight New Data at Upcoming ESC Congress 2013
4. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
5. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
6. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
7. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
8. Amgen Announces Webcast of 2013 Second Quarter Financial Results
9. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
(Date:9/19/2014)... Sept. 19, 2014  PCI is pleased to ... Biotec is a leading provider of Clinical Trial ... Bridgend, Wales in the ... significantly expands PCI,s presence in the UK/EU to ... adding packaging, storage and distribution capacity, as well ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... ORANGE COUNTY, Calif., Sept. 8 Beckman Coulter, Inc. (NYSE: ... of products that simplify, automate, and innovate complex biomedical testing, ... conferences: Morgan Stanley 2010 Healthcare Conference on Monday, ... City, New York. Stifel Nicolaus 2010 Healthcare Conference on ...
... SAN MARINO, Calif., Sept. 7 Epeius Biotechnologies Corporation, ... medicine, reports the publication of a landmark paper in ... I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic ... gained both Orphan Drug and FDA Fast Track Status, ...
Cached Medicine Technology:Beckman Coulter to Present at Upcoming Healthcare Conferences 2To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles' 2
(Date:9/21/2014)... UNIWIGS, one of the leading online stores ... pieces, offers a line of human hair lace wigs inspired ... also shows people what the latest celebrity hairstyles ... there are 4 different hairstyles to choose from: a style ... lace wigs and a hot ombre red lace wig. People ...
(Date:9/21/2014)... More than a quarter of house fires are ... of two ways. The first type of dryer fire occurs ... type of dryer fire occurs when lint builds up in the ... due to malfunctioning electrical systems so if it doesn’t appear to ... Here are some ways that you can prevent dryer fires. , ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Expert witness ... released the findings from its 2014 Expert Witness Fees ... increasingly complex, the demand and compensation for qualified and ... in the Survey’s 16-year history. , The nearly ... hour for their expert work, an increase of 3.2% ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... "I want to help people who are having ... money for chiropractors," said an inventor from St. Amat, ... for myself." , The Stretch is a device that ... and align the spine properly. It improves flexibility and ... nerves. Compact and easy to use, it's ideal for ...
Breaking Medicine News(10 mins):Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2
... of deadly neuroectodermal tumors , MONDAY, Dec. 7 (HealthDay ... role in a particularly aggressive type of childhood brain ... tumors (CNS-PNETs), the discovery of these oncogenes may lead ... , "Lack of insight into the molecular pathogenesis of ...
... , , SAN FRANCISCO, Dec. 7 Senior advocacy organizations ... grant from Verizon on Tuesday (Dec. 8) to continue the Commitment to End Abuse ... Hank Lacayo, president and CEO, Congress of California Seniors, ... and CEO, Self-Help for the Elderly, ...
... , GREENDALE, Wis., Dec. 7 Taste of Home ... Comfort Food Diet Cookbook, featuring America,s favorite comfort recipes with ... Food Diet Cookbook , on shelves December 31, 2009, is a ... pounds without feeling deprived. Enjoy pizza, lasagna, mac-n-cheese, pulled pork and ...
... ― The second-generation proteasome inhibitor carfilzomib is showing noteworthy ... among multiple myeloma patients in a phase II clinical ... of the American Society of Hematology. The updated ... relapsed or resistant multiple myeloma who have received one ...
... ... dental emergency, finding a qualified, experienced dentist is a crucial step in preserving your smile ... Minneapolis, ... stand against the high prices and inconvenience of emergency dental procedures. Whether a tooth is ...
... fewer hassles, study finds , MONDAY, Dec. 7 (HealthDay News) ... just as effective in preventing dangerous venous clots as an ... to manage, a new study finds. , Dabigatran is marketed ... not yet approved for use in the United States. , ...
Cached Medicine News:Health News:New Target May Be Eyed in Kids' Brain Cancer 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 3Health News:Drug shows positive responses, low side-effects in multiple myeloma 2Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: